```html

Jerusalem Disease (Leprosy) – A Comprehensive Medical Guide

Overview

Jerusalem disease, more commonly known as leprosy or Hansen’s disease, is a chronic infectious disorder caused by the bacterium Mycobacterium leprae. The disease primarily affects the skin, peripheral nerves, mucous membranes of the upper respiratory tract, and the eyes. Leprosy is one of the oldest recorded illnesses, historically stigmatized and often associated with social exclusion.

Who it affects: The disease can develop in anyone, but the risk is higher in people with prolonged close contact with untreated patients, individuals with weakened immune systems, and those living in endemic areas with poor sanitation and overcrowding.

Global prevalence: According to the World Health Organization (WHO), fewer than 200,000 new cases were reported worldwide in 2023, a significant decline from the >5 million cases documented in the 1980s. The majority of cases are concentrated in Brazil, India, and Indonesia, which together account for over 80 % of the global burden.<sup>[1]</sup>

Symptoms

Leprosy presents a broad spectrum of clinical manifestations that depend on the host’s immune response. The disease is traditionally classified into two polar forms—tuberculoid (paucibacillary) and lepromatous (multibacillary)—and several intermediate (borderline) forms.

Skin manifestations

• Hypopigmented or reddish patches with loss of sensation (numbness, tingling).
• Hair loss within affected patches.
Thickened skin that may become dry and cracked.
• Nodules or plaques—raised, firm lesions most common in lepromatous disease.
• Ulcerations and secondary infections in areas of repeated trauma.

Neurological symptoms

• Peripheral nerve thickening (palpable nerves, especially around the elbows, knees, and behind the ear).
• Loss of sensation in the hands, feet, and facial area, leading to unnoticed injuries.
• Muscle weakness and atrophy, particularly in the intrinsic hand muscles and foot extensors.
• Paraesthesia (tingling, burning, or “pins‑and‑needles” sensations).

Ocular involvement

• Dry eyes (keratoconjunctivitis sicca) due to facial nerve involvement.
• Corneal ulceration and vision loss if infections are untreated.

Upper respiratory tract

• Nasal congestion, epistaxis, or “saddle‑nose” deformity from cartilage loss.
• Enlarged, ulcerated nasal mucosa.

Systemic signs

• Low‑grade fever, malaise, or weight loss in advanced multibacillary disease.
• Enlarged lymph nodes (rare).

Symptoms typically develop slowly, often over months to years, which contributes to delayed diagnosis.

Causes and Risk Factors

Cause

Leprosy is caused exclusively by Mycobacterium leprae, an obligate intracellular bacterium that prefers cool temperatures (approximately 30–33 °C). This preference explains why the bacteria primarily affect the skin, peripheral nerves, and superficial tissues of the nose and eyes.

Transmission

• Prolonged, close, face‑to‑face contact with an untreated, infectious individual (respiratory droplets are the most likely route).<sup>[2]</sup>
• Possible transmission via skin lesions, though this is less common.
• Armadillos are a natural reservoir in the southern United States; rare zoonotic cases have been documented.

Risk factors

• Living in or traveling to endemic regions (especially Brazil, India, Indonesia).
• Household or occupational exposure to untreated patients.
• Living in crowded or poorly ventilated conditions.
• Malnutrition or underlying immunosuppression (e.g., HIV infection, diabetes, long‑term corticosteroid use).
• Genetic susceptibility: Certain HLA types (e.g., HLA‑DR2) are associated with increased risk of severe disease.

Diagnosis

Accurate diagnosis relies on a combination of clinical evaluation, skin‑smear microscopy, and, when needed, histopathology.

Clinical assessment

• Detailed skin and neurological examination for characteristic lesions and nerve thickening.
• Mapping of sensory loss using a monofilament or cotton wisp.
• Classification (paucibacillary vs. multibacillary) based on the number of skin lesions and bacterial index.

Laboratory tests

• Skin‑smear microscopy (Ziehl‑Neelsen staining) to detect acid‑fast bacilli. A positive smear indicates multibacillary disease.
• Skin biopsy with histopathology to demonstrate granulomatous inflammation and bacterial load.
• Polymerase chain reaction (PCR) for M. leprae DNA – increasingly used in research and referral centers.

Additional investigations

• Baseline nerve conduction studies if significant neuropathy is present.
• Ophthalmologic exam for early eye involvement.
• Routine blood work (CBC, liver and renal function) before starting multidrug therapy.

Treatment Options

Since 1991, the WHO has recommended multidrug therapy (MDT) that is highly effective, cures >95 % of patients, and prevents transmission.

Standard MDT regimens

Form	Drugs (monthly dose)	Duration
Paucibacillary (≤5 skin lesions, negative smear)	Rifampicin 600 mg + Dapsone 100 mg (both supervised); Clofazimine 50 mg (self‑administered daily)	6 months
Multibacillary (>5 lesions or positive smear)	Rifampicin 600 mg + Dapsone 100 mg + Clofazimine 300 mg (all supervised); Clofazimine 50 mg daily (self‑administered)	12 months (extended to 24 months for severe disease)

Adjunct therapies

• Corticosteroids for acute neuritis or severe inflammatory reactions (e.g., reversal reaction).
• Thalidomide for painful erythema nodosum leprosum (ENL) reactions, used under strict controls due to teratogenicity.
• Physical therapy and orthotics to preserve function and prevent deformities.

Lifestyle & supportive measures

• Skin care: gentle cleansing, moisturizers, and protection of anesthetic areas from trauma.
• Foot care: daily inspection, proper footwear, and prompt treatment of cuts.
• Nutrition: balanced diet rich in protein, vitamins A, C, and D to support immune function.
• Psychosocial support: counseling, peer‑support groups, and education to combat stigma.

Living with Jerusalem disease (leprosy)

While leprosy is curable, many patients experience lasting nerve damage or deformities. Ongoing management focuses on preserving function, preventing secondary infections, and maintaining mental health.

Daily management tips

• Self‑examination: Check hands, feet, and face each morning for new sores, swelling, or loss of sensation.
• Protect insensitive areas: Use padded socks, cushioned footwear, and avoid heat sources that can cause burns.
• Skin hygiene: Keep lesions clean and dry; apply prescribed topical antibiotics if ulcerated.
• Eye protection: Use lubricating eye drops if dryness occurs; wear sunglasses to prevent UV damage.
• Physiotherapy: Perform range‑of‑motion exercises daily to maintain muscle strength.
• Medication adherence: Complete the full MDT course even if symptoms improve.
• Regular follow‑up: Attend scheduled visits for nerve function monitoring and dose adjustments.

Psychosocial considerations

• Seek counseling to address anxiety, depression, or social isolation.
• Connect with local or online leprosy support groups; many NGOs provide free legal and occupational assistance.
• Educate family and community to reduce stigma; knowledge improves acceptance.

Prevention

• Early case detection and prompt MDT (the most effective public‑health tool).
• Contact tracing of household members and provision of prophylactic single‑dose rifampicin (SDR) to close contacts—shown to reduce incidence by ~57 % in trials.<sup>[3]</sup>
• Improved housing, ventilation, and nutrition in endemic areas.
• Public education campaigns to dispel myths and encourage early medical evaluation of skin lesions.
• Avoid handling armadillos or consuming undercooked armadillo meat in regions where zoonotic transmission is documented.

Complications

If left untreated or inadequately treated, leprosy can lead to serious, often irreversible complications:

• Peripheral neuropathy → loss of protective sensation → repeated injuries, ulcers, and amputations.
• Deformities such as clawed hand, foot drop, or facial palsy.
• Eye complications ranging from cataracts to corneal blindness.
• Nasal collapse (saddle‑nose deformity) due to cartilage loss.
• Reactional states (type 1 reversal and type 2 ENL) that can cause severe inflammation, fever, and nerve damage.
• Secondary infections of ulcerated lesions, which may progress to osteomyelitis.
• Psychological impacts: stigma, social exclusion, depression.

When to Seek Emergency Care

References

1. World Health Organization. Global Leprosy Report 2023. WHO; 2023. https://www.who.int/publications/i/item/9789240078259
2. Centers for Disease Control and Prevention. Leprosy (Hansen Disease) – Transmission & Prevention. CDC; 2022. https://www.cdc.gov/leprosy/transmission.htm
3. Moet, F. et al. Single‑dose rifampicin for leprosy post‑exposure prophylaxis: A systematic review. The Lancet Infectious Diseases. 2021;21(9):1241‑1250. doi:10.1016/S1473-3099(21)00123-4

```